Correlation between RPPA expression and clinical features
Uterine Corpus Endometrioid Carcinoma (Primary solid tumor)
28 January 2016  |  analyses__2016_01_28
Maintainer Information
Citation Information
Maintained by Juok Cho (Broad Institute)
Cite as Broad Institute TCGA Genome Data Analysis Center (2016): Correlation between RPPA expression and clinical features. Broad Institute of MIT and Harvard. doi:10.7908/C11Z43XW
Overview
Introduction

This pipeline uses various statistical tests to identify RPPAs whose expression levels correlated to selected clinical features. The input file "UCEC-TP.rppa.txt" is generated in the pipeline RPPA_AnnotateWithGene in the stddata run.

Summary

Testing the association between 208 genes and 4 clinical features across 440 samples, statistically thresholded by P value < 0.05 and Q value < 0.3, 3 clinical features related to at least one genes.

  • 30 genes correlated to 'DAYS_TO_DEATH_OR_LAST_FUP'.

    • CHEK2|CHK2_PT68 ,  ESR1|ER-ALPHA_PS118 ,  AKT1 AKT2 AKT3|AKT ,  TP53|P53 ,  ANXA1|ANNEXIN-1 ,  ...

  • 1 gene correlated to 'RADIATION_THERAPY'.

    • SRSF1|SF2

  • 30 genes correlated to 'HISTOLOGICAL_TYPE'.

    • TP53|P53 ,  AKT1 AKT2 AKT3|AKT_PS473 ,  AKT1 AKT2 AKT3|AKT_PT308 ,  CHEK2|CHK2_PT68 ,  ESR1|ER-ALPHA_PS118 ,  ...

  • No genes correlated to 'RESIDUAL_TUMOR'

Results
Overview of the results

Complete statistical result table is provided in Supplement Table 1

Table 1.  Get Full Table This table shows the clinical features, statistical methods used, and the number of genes that are significantly associated with each clinical feature at P value < 0.05 and Q value < 0.3.

Clinical feature Statistical test Significant genes Associated with                 Associated with
DAYS_TO_DEATH_OR_LAST_FUP Cox regression test N=30   N=NA   N=NA
RADIATION_THERAPY Wilcoxon test N=1 yes N=1 no N=0
HISTOLOGICAL_TYPE Kruskal-Wallis test N=30        
RESIDUAL_TUMOR Kruskal-Wallis test   N=0        
Clinical variable #1: 'DAYS_TO_DEATH_OR_LAST_FUP'

30 genes related to 'DAYS_TO_DEATH_OR_LAST_FUP'.

Table S1.  Basic characteristics of clinical feature: 'DAYS_TO_DEATH_OR_LAST_FUP'

DAYS_TO_DEATH_OR_LAST_FUP Duration (Months) 0.1-185.8 (median=28.8)
  censored N = 364
  death N = 75
     
  Significant markers N = 30
  associated with shorter survival NA
  associated with longer survival NA
List of top 10 genes differentially expressed by 'DAYS_TO_DEATH_OR_LAST_FUP'

Table S2.  Get Full Table List of top 10 genes significantly associated with 'Time to Death' by Cox regression test. For the survival curves, it compared quantile intervals at c(0, 0.25, 0.50, 0.75, 1) and did not try survival analysis if there is only one interval.

logrank_P Q C_index
CHEK2|CHK2_PT68 9.36e-05 0.019 0.617
ESR1|ER-ALPHA_PS118 0.000382 0.025 0.368
AKT1 AKT2 AKT3|AKT 0.000441 0.025 0.605
TP53|P53 0.000554 0.025 0.612
ANXA1|ANNEXIN-1 0.000601 0.025 0.356
AKT1 AKT2 AKT3|AKT_PT308 0.00212 0.073 0.409
ESR1|ER-ALPHA 0.00259 0.077 0.342
CTNNB1|BETA-CATENIN 0.00302 0.078 0.454
RPS6KA1|P90RSK 0.00498 0.12 0.366
CDH1|E-CADHERIN 0.00639 0.13 0.38
Clinical variable #2: 'RADIATION_THERAPY'

One gene related to 'RADIATION_THERAPY'.

Table S3.  Basic characteristics of clinical feature: 'RADIATION_THERAPY'

RADIATION_THERAPY Labels N
  NO 228
  YES 192
     
  Significant markers N = 1
  Higher in YES 1
  Higher in NO 0
List of one gene differentially expressed by 'RADIATION_THERAPY'

Table S4.  Get Full Table List of one gene differentially expressed by 'RADIATION_THERAPY'

W(pos if higher in 'YES') wilcoxontestP Q AUC
SRSF1|SF2 17901 0.001296 0.27 0.5911
Clinical variable #3: 'HISTOLOGICAL_TYPE'

30 genes related to 'HISTOLOGICAL_TYPE'.

Table S5.  Basic characteristics of clinical feature: 'HISTOLOGICAL_TYPE'

HISTOLOGICAL_TYPE Labels N
  ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA 329
  MIXED SEROUS AND ENDOMETRIOID 17
  SEROUS ENDOMETRIAL ADENOCARCINOMA 94
     
  Significant markers N = 30
List of top 10 genes differentially expressed by 'HISTOLOGICAL_TYPE'

Table S6.  Get Full Table List of top 10 genes differentially expressed by 'HISTOLOGICAL_TYPE'

kruskal_wallis_P Q
TP53|P53 1.813e-21 3.77e-19
AKT1 AKT2 AKT3|AKT_PS473 4.671e-21 4.86e-19
AKT1 AKT2 AKT3|AKT_PT308 1.664e-20 1.15e-18
CHEK2|CHK2_PT68 9.25e-20 4.81e-18
ESR1|ER-ALPHA_PS118 2.99e-15 1.24e-13
CCNE1|CYCLIN_E1 9.611e-15 3.33e-13
PIK3CA |PI3K-P110-ALPHA 1.668e-14 4.96e-13
ESR1|ER-ALPHA 3.896e-14 1.01e-12
PTEN|PTEN 4.647e-10 1.07e-08
ANXA1|ANNEXIN-1 1.784e-09 3.71e-08
Clinical variable #4: 'RESIDUAL_TUMOR'

No gene related to 'RESIDUAL_TUMOR'.

Table S7.  Basic characteristics of clinical feature: 'RESIDUAL_TUMOR'

RESIDUAL_TUMOR Labels N
  R0 301
  R1 14
  R2 11
  RX 37
     
  Significant markers N = 0
Methods & Data
Input
  • Expresson data file = UCEC-TP.rppa.txt

  • Clinical data file = UCEC-TP.merged_data.txt

  • Number of patients = 440

  • Number of genes = 208

  • Number of clinical features = 4

Selected clinical features
  • Further details on clinical features selected for this analysis, please find a documentation on selected CDEs (Clinical Data Elements). The first column of the file is a formula to convert values and the second column is a clinical parameter name.

  • Survival time data

    • Survival time data is a combined value of days_to_death and days_to_last_followup. For each patient, it creates a combined value 'days_to_death_or_last_fup' using conversion process below.

      • if 'vital_status'==1(dead), 'days_to_last_followup' is always NA. Thus, uses 'days_to_death' value for 'days_to_death_or_fup'

      • if 'vital_status'==0(alive),

        • if 'days_to_death'==NA & 'days_to_last_followup'!=NA, uses 'days_to_last_followup' value for 'days_to_death_or_fup'

        • if 'days_to_death'!=NA, excludes this case in survival analysis and report the case.

      • if 'vital_status'==NA,excludes this case in survival analysis and report the case.

    • cf. In certain diesase types such as SKCM, days_to_death parameter is replaced with time_from_specimen_dx or time_from_specimen_procurement_to_death .

  • This analysis excluded clinical variables that has only NA values.

Survival analysis

For survival clinical features, logrank test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values comparing quantile intervals using the 'coxph' function in R. Kaplan-Meier survival curves were plotted using quantile intervals at c(0, 0.25, 0.50, 0.75, 1). If there is only one interval group, it will not try survival analysis.

Wilcoxon rank sum test (Mann-Whitney U test)

For two groups (mutant or wild-type) of continuous type of clinical data, wilcoxon rank sum test (Mann and Whitney, 1947) was applied to compare their mean difference using 'wilcox.test(continuous.clinical ~ as.factor(group), exact=FALSE)' function in R. This test is equivalent to the Mann-Whitney test.

Q value calculation

For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.

Download Results

In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.

References
[1] Andersen and Gill, Cox's regression model for counting processes, a large sample study, Annals of Statistics 10(4):1100-1120 (1982)
[2] Mann and Whitney, On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other, Annals of Mathematical Statistics 18 (1), 50-60 (1947)
[3] Benjamini and Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society Series B 59:289-300 (1995)